56 results about "Chronic skin ulcers" patented technology

Matrix metalloproteinases are major mediators of tissue destruction in various chronic inflammatory disorders. The present invention demonstrates that over- expression of intracellular isoform of IL-1 receptor antagonist confers to recipient cells resistance to signaling pathways of proinflammatory cytokines (such as tumor necrosis factor alpha and IL-1 beta) that induce matrix metalloproteinase and subsequent tissue degradation. Hence, over-expression of intracellular IL-1 receptor antagonist may inhibit tissue destruction in various inflammatory disorders such as rheumatoid arthritis, other arthritides, degenerative intervertebral disc disease and chronic skin ulcers that occurs in diabetes mellitus and bed-ridden patients.

Matrix metalloproteinases are major mediators of tissue destruction in various chronic inflammatory disorders. The present invention demonstrates that over-expression of intracellular isoform of IL-1 receptor antagonist confers to recipient cells resistance to signaling pathways of proinflammatory cytokines (such as tumor necrosis factor alpha and IL-1 beta) that induce matrix metalloproteinase and subsequent tissue degradation. Hence, over-expression of intracellular IL-1 receptor antagonist may inhibit tissue destruction in various inflammatory disorders such as rheumatoid arthritis, other arthritides, degenerative intervertebral disc disease and chronic skin ulcers that occurs in diabetes mellitus and bed-ridden patients.

The invention relates to an externally applied preparation for treating skin wound, in particular to an externally applied preparation for treating chronic skin ulcer, which is characterized in that it comprises the effective components in weight as follows: insulin 500-5000u / 1000g, epidermal growth factor 0.001-0.01g / 1000g, antibacterials 5-20g / 1000g, others are adjuvant. It can treat a variety of infectious and protracted skin ulcer safely and effectively.

Matrix metalloproteinases are major mediators of tissue destruction in various chronic inflammatory disorders. The present invention demonstrates that over-expression of intracellular isoform of IL-1 receptor antagonist confers to recipient cells resistance to signaling pathways of proinflammatory cytokines (such as tumor necrosis factor alpha and IL-1 beta) that induce matrix metalloproteinase and subsequent tissue degradation. Hence, over-expression of intracellular IL-1 receptor antagonist may inhibit tissue destruction in various inflammatory disorders such as rheumatoid arthritis, other arthritides, degenerative intervertebral disc disease and chronic skin ulcers that occurs in diabetes mellitus and bed-ridden patients.

The invention relates to an externally-applied traditional Chinese medicine preparation for accelerating healing of chronic skin ulcer wounds and a preparation method thereof. According to the preparation, root of angelica sinensis(oliv.)diels, frankincense, commiphora myrrha engl.[c.molmol engl.], daemonorops draco blume., flower of carthamus tinctorius l. and dried body of eupolyphaga sinensis walker are used as monarch drugs capable of promoting blood circulation, removing obstruction in collaterals and relieving pain; unprocessed rehmannia root, root of paeonia veitchii lynch, root of scrophularia ningpoensis hemsl., root of rheum palmatum L. and root of lithospermum erythrorhizon sieb.et zucc. are used as ministerial drugs capable of cooling blood, relieving pain, detoxifying, and reinforcing the pain relieving effects of the monarch drugs; root of sophora flavescens ait. and cortex of phellodendron chinense Schneid. are capable of clearing heat and drying dampness; root of angelica dahurica (Fisch.ex Hoffm.) Benth.et Hook.f., root of notopterygium incisum ting ex h.t.chang and angelica pubescens Maxim.f.biserrata Shan et Yuan have the effects of dispelling wind and eliminating dampness; the root of sophora flavescens ait., the cortex of phellodendron chinense schneid., the root of angelica dahurica(Fisch.ex Hoffm.) Benth.et Hook.f., the root ofnotopterygium incisum tingex h.t.chang and the root of angelica pubescens Maxim.f.biserrata Shan et Yuan can cooperate with one another to remove damp heat toxin and fire toxin formed when circulation of qi and blood is unsmooth and qi and blood overflow outside veins due to stasis and blockage of blood vessels; the damp heat toxin and fire toxin are accumulated subcutaneously to form lumps; tuber of ampelopsis japonica(Thunb.)Makino, momordica cochinchinensis(Lour.)Spreng. and forsythia suspensa(thunb.)vahl are used to assist in clearing heat, removing stasis and diminishing swelling; the sophora flavescens ait., thephellodendron chinense schneid., the angelica dahurica(fisch.ex hoffm.)benth.et hook.f., the notopterygium incisum ting ex h.t.chang, angelica pubescens maxim.f.biserrata shan et yuan, the ampelopsisjaponica(thunb.)makino, seed of momordica cochinchinensis(Lour.)Spreng. and fruit of forsythia suspensa(Thunb.)Vahl are jointly used as adjuvant drugs; cinnamomum cassia presl, tuber of lindera aggregata(Sims)Kosterm. and borneol are capable of inducing menstruation to relieve menalgia and reinforcing the pain relieving effects of the monarch drugs; bletilla striata(Thunb.)Reichb.f. is capable ofdiminishing swelling and promoting granulation; the cinnamomum cassia presl, the lindera aggregata(sims)kosterm., the borneol and the rhizome of bletilla striata(Thunb.)Reichb.f. are jointly used as envoy drugs. Through treatment and follow-up on multiple patients with diabetic foot gangrene and decubital ulcer, the total effective rate is 100%.

This invention relates to methods for treating chronic dermal ulcers using hyperbaric treatment in combination with progenitor cells and chemokine homing factors. Specifically, the invention relates to treatment of chronic wounds resulting from diabetes mellitus using compositions comprising EPC and SDF-1A, under hyperbaric condition to accelerate wound healing.

The invention provides a preparation method of a gel containing a fibroblast growth factor-1 modified body and an application thereof for treating chronic skin ulcer caused by diabetic foot. The gel disclosed by the invention comprises the following components: 20000-80000 IU of recombinant human fibroblast growth factor-1 modified body (FGF-1135) protein, 10 pg to 40 mu g of low molecular weight heparin sodium, 0.2-1.0 g of glycerol, 50-150 mg of a protein protectant, and 0.03-0.05g of a gel substrate, wherein the pH value is adjusted; and water for injection is added to be 10 ml. Compared with the original sequence, the fibroblast growth factor-1 modified body used in the invention is more steady; after being prepared into the gel, the fibroblast growth factor-1 modified body is more convenient for clinical application; the better stability and slow-release effects can be achieved; the bioavailability of protein is increased; the gel is more beneficial to treating diabetic foot; and the gel can be also used for treating burning, scalding and other chronic and refractory ulcers.

Artificial dermis (1) obtained from plasma with platelets (2) and human fibroblasts. The plasma with platelets (2) is obtained from the fractionating of total blood (4) from the patient (8) by light centrifugation, and the human fibroblasts (3) from a skin biopsy (5). Clotting is obtained by adding calcium.This artificial dermis (1) provides for the rapid growth of the keratinocytes (6) seeded on its surface to build an artificial skin (7) which can easily be transplanted. Large areas of artificial dermis (1) are obtained from a small skin biopsy (5) and minimal quantities of plasma with platelets (2), which being enriched with cytokines and platelet growth factors, strengthens the proliferation of the cells seeded, both inside and on the surface.The artificial skin (7) obtained can be used to treat major burn treatments, chronic skin ulcers, etc., or be used, by employing genetically altered cells, as a vehicle for gene therapy.

This invention relates to methods for treating chronic dermal ulcers using hyperbaric treatment in combination with progenitor cells and chemokine homing factors. Specifically, the invention relates to treatment of chronic wounds resulting from diabetes mellitus using compositions comprising EPC and SDF-1A, under hyperbaric condition to accelerate wound healing.